- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
The First OTC Nasal Spray Form of Naloxone Approved by FDA to Treat Opioid Overdoses
In an effort to combat opioid overdoses, the FDA has just authorised the first naloxone medication available without a prescription. Naloxone hydrochloride nasal spray 4 mg (Narcan®, Emergent BioSolutions) was approved by the FDA, according to a news release. The FDA emphasised that access to other naloxone formulations and doses will continue to be restricted to those with a valid prescription.
Naloxone nasal spray has been approved for sale over the counter, which will boost the availability of the drug, make it easier to administer, and ultimately save lives by preventing opioid overdoses. In a statement, FDA Commissioner Robert M. Califf, MD, urged the producer to prioritise patient access by making the medicine widely accessible as quickly as feasible at a reasonable price.
The FDA reports that fatal drug overdoses remain a serious problem in the United States, with over 101,750 deaths expected in the year ending in October 2022. This increase is due mostly to the increased use of synthetic opioids like illegal fentanyl. The nasal spray may now be offered to the general public without a prescription, through retail outlets like supermarkets and convenience shops, as well as on the internet.
The manufacturer data showed that the medicine is safe and effective for use as advised in the proposed labelling, thus the FDA decided to make naloxone nasal spray available without a prescription. The FDA also noted that the producer provided evidence that the public may learn to use naloxone efficiently and safely without medical supervision.
In 2015, the FDA approved the first naloxone nasal spray prescriptions. Priority review was granted by the FDA in December 2022 after a second new drug application for Narcan's over-the-counter usage was submitted. The advisory committee members then all agreed in February 2023 to that the drug be made available without a prescription.
The FDA has made it clear that the existing authorised 4 mg generic naloxone nasal spray products that use Narcan as their reference listed drug product will need to have their labels revised in order to get clearance. In order to transition these medications to OTC status, the FDA has said that manufacturers must file a supplemental application. In addition, the clearance may have implications for the availability of additional brand-name naloxone nasal spray products with a 4 mg dose, but "determinations will be made on a case-by-case basis and the FDA may contact other firms as needed," according to the FDA.
During the transition of this medication from prescription status to nonprescription/OTC status, the FDA is working with our federal partners to assist assure continuing access to all forms of naloxone, according to PatriziaCavazzoni, MD, director, Centre for Drug Evaluation and Research, FDA. "Further, we will work with any sponsor seeking to market a nonprescription naloxone product, including through a Rx to OTC switch, and we encourage manufacturers to contact the agency as early as possible to initiate discussions."
The company Emergency BioSolutions expects to have Narcan for sale in its stores and on its website before the end of the summer. The corporation said in a press statement that "the prescription product will remain in readily available supply through existing access channels, including pharmacies through standing order or co-prescription laws and through community distribution."
Reference - https://investors.emergentbiosolutions.com/news-releases/news-release-details/us-fda-approves-over-counter-designation-emergent-biosolutions
MBBS, MD (Anaesthesiology), FNB (Cardiac Anaesthesiology)
Dr Monish Raut is a practicing Cardiac Anesthesiologist. He completed his MBBS at Government Medical College, Nagpur, and pursued his MD in Anesthesiology at BJ Medical College, Pune. Further specializing in Cardiac Anesthesiology, Dr Raut earned his FNB in Cardiac Anesthesiology from Sir Ganga Ram Hospital, Delhi.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751